MUSK and myasthenia gravis: Telitacicept (RC18), an inhibitor of the B cell activation factor (BAFF), demonstrated efficacy in reducing clinical severity in generalized MG in a phase II study (164), but this study was not able to recruit MuSK-MG patients.